This study is an open label extension study to confirm the long term safety and efficacy of eculizumab in subjects with relapsing NMO who have completed the initial double-blind, randomized, placebo-controlled trial ECU-NMO-301.
The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.